

## PHARMACY POLICY STATEMENT North Carolina Marketplace

<b>DRUG NAME</b>	<b>Ryplazim (plasminogen, human-tvmh)</b>
BILLING CODE	J3590
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Home/Office/Outpatient
STATUS	Prior Authorization Required

Ryplazim (plasminogen, human-tvmh) is plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). It was approved by the FDA on June 4, 2021 and is the first approved treatment for plasminogen deficiency type 1.

Indiv TJEMC ET/Artifact BMC 1 g50.4 458.4 525.6 12.6 refEMC BT/P A MCID 92 BDC 0 g0.061 Tw 11.04 -0 0 11.04 5

